Journal
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
Volume 181, Issue -, Pages 93-100Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.pbb.2019.05.002
Keywords
Cannabidiol (CBD); Fragile X syndrome; Mouse model; Locomotion; Anxiety; Cognition; Social behaviours
Funding
- Zynerba Pharmaceuticals, USA
- National Health and Medical Research Council (NHMRC) [1045643]
- NHMRC [1102012, 1141789]
- NHMRC dementia research team initiative [1095215]
- A.M. Wood Scholarship from the Schizophrenia Research Institute
- NHMRC CJ Martin Fellowship [1072878]
- Zynerba Pharmaceuticals Inc.
- Bohringer Ingleheim
- Astellas Pharma Inc.
- National Health and Medical Research Council of Australia [1141789, 1072878] Funding Source: NHMRC
Ask authors/readers for more resources
Fragile X Syndrome is a neurodevelopmental disorder which affects intellectual, social and physical development due to mutation of the Fragile X mental retardation 1 (FMR1) gene. The resultant loss of Fragile X mental retardation protein can be modelled by Fmr1 gene knockout (KO) in mice. The current study investigated the behavioural effects of cannabidiol (CBD; a non-psychoactive phytocannabinoid) in male Fmr1 KO mice as a preclinical model for therapeutic discovery. Vehicle or CBD (5 or 20 mg/kg body weight) was administered to adult Fmr1 KO and wild type-like (WT) mice before they were tested in behavioural tasks including: open field (OF), elevated plus maze (EPM), spontaneous alternation, social preference, and passive avoidance tasks. Fmr1 KO mice were hyperlocomotive and hyperexplorative and habituated more slowly to a novel environment compared to control animals. Furthermore, Fmr1 KO mice showed fewer anxiety-related behaviours across tests. Effects of CBD were subtle and limited to the EPM, where CBD decreased the anxiety response of all mice tested. Acute CBD had no impact on locomotion or anxiety-related parameters in the OF. Cognitive performance of Fmr1 KO mice was equivalent to controls and not affected by CBD treatment. Brain concentrations of CBD were equivalent between genotypes, but in animals sacrificed 90 min post-administration, decreased plasma CBD in Fmr1 KO mice compared to WT suggested more rapid clearance of CBD by transgenic animals. Overall, acute CBD at the doses chosen did not selectively normalize behavioural abnormalities in Fmr1 KO mice, but reduced anxiety-like behaviour in both Fmr1 KO and WT mice.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available